Application of m6A methylation modified circIST1 in diagnosis, treatment and prognosis of liver cancer

By discovering and verifying the role of circIST1, using its m6A methylation modification and silencing technology, the shortcomings in diagnosis and prognosis evaluation and the problem of HIF-1α inhibition are solved, and the efficient diagnosis and treatment targets of liver cancer are achieved, and the patients are improved. Diagnostic and therapeutic accuracy.

CN118956868APending Publication Date: 2024-11-15THE THIRD AFFILIATED HOSPITAL OF PLA NAVAL MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411038432.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-31
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art has not yet effectively utilized circRNA in the diagnosis, prognosis evaluation and treatment of liver cancer, and there are few targeted drugs for liver cancer, and the role of the hypoxia-induced factor HIF-1α in the development of liver cancer has not been effectively inhibited.

Method used

It was discovered and verified that circIST1, as a new liver cancer-related circRNA, was modified by m6A methylation to silence its expression to promote the negative regulation of HIF-1α by miR-140-3p and miR-182, and prevent the malignant proliferation of liver cancer cells. and metastasis and development of kits for diagnosis and prognosis evaluation of liver cancer, as well as drugs for silencing or inhibition of circIST1.

Benefits of technology

The high expression of circIST1 indicates a poor clinical prognosis in patients with liver cancer. By silencing its expression, it can inhibit the expression of HIF-1α, prevent the malignant progression of liver cancer cells, provide new diagnostic markers and therapeutic targets, and improve the liver cancer. Diagnostic and therapeutic accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956868A_ABST
    Figure CN118956868A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and particularly provides a brand-new circular RNA molecule circIST1 and application of the brand-new circular RNA molecule circIST1 in liver cancer diagnosis, prognosis evaluation and treatment. The circIST1 related to the liver cancer is found for the first time, it is proved that the circIST1 participates in malignant progression of the liver cancer and can serve as a potential diagnosis and treatment target, and a scientific, precise and personalized diagnosis and treatment scheme is provided for a patient with the liver cancer through the expression level of the circIST1 in the body of the patient.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to circIST1 modified by m6A methylation and its use in diagnosis, prognosis evaluation and treatment of liver cancer. Background Art

[0002] Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma and other rare types, of which HCC accounts for 75% to 85%. Hepatocellular carcinoma (hereinafter referred to as liver cancer) has the characteristics of insidious onset, no obvious symptoms in the early stage, and most patients are already in the middle and late stages when diagnosed. Currently, there are few targeted drugs for liver cancer. Exploring new molecular therapeutic targets and designing new targeted drugs are hot issues in the field of liver cancer research.

[0003] Circular RNA (circRNA) is a new type of non-coding RNA characterized by a covalent closed loop structure, no 5' to 3' polarity, and no polyadenylated tail. The latest studies have shown that circRNAs can act as competitive endogenous RNAs (ceRNAs) to regulate gene expression, and can also act as sponges for microRNAs (miRNAs) to block the negative regulatory effects of miRNAs on target genes. Studies have shown that circRNAs are involved in the malignant progression of liver cancer, such as malignant proliferation and metastasis, and can be used as molecular therapeutic targets for liver cancer.

[0004] There is currently no report on the application of the circRNA of the present invention in the diagnosis, treatment and prognosis of liver cancer. Summary of the invention

[0005] The present invention discovered a new liver cancer-related circRNA, named circIST1. The circRNA is located on chromosome 16, 71954641-71957283 sequence, and is composed of the first splicing of exons 6, 7, 8, and 9 of the IST1 gene, and its cyclized nucleotide sequence has 495 bases. The purpose of the present invention is to provide a circIST1 modified by m6A methylation and its use in liver cancer diagnosis, prognosis evaluation and treatment.

[0006] Hypoxia-inducible factor (HIF) is a core molecule in the cell's response to hypoxia. It is a transcription factor composed of hypoxia-regulated α and oxygen-sensitive β subunits. In the absence of oxygen, human cells activate a series of signaling pathways, including hypoxia-inducible factor, energy metabolism pathways, and cell stress pathways, thereby inducing cellular stress responses to hypoxia. The HIF signaling pathway has the functions of sensing metabolic changes caused by cellular hypoxia, regulating cell proliferation, and inducing inflammatory responses.

[0007] Studies have shown that hypoxia-inducible factor HIF-1α plays an important role in regulating the occurrence and development of liver cancer, including epithelial-mesenchymal transition (EMT) and invasion of the extracellular matrix. In addition, HIF-1α induces the transcription of genes involved in angiogenesis, glucose metabolism, proliferation, invasion and metastasis in HCC, promoting the progression of liver cancer. How to inhibit the expression of HIF-1α is a new entry point for the treatment of liver cancer.

[0008] The present invention shows through in vivo and in vitro experiments that silencing the expression of circular RNA IST1 in liver cancer can promote the negative regulatory effect of miR-140-3p and miR-182 on HIF-1α, thereby inhibiting the expression of HIF-1α and preventing the malignant proliferation and metastasis of liver cancer cells.

[0009] In order to explore the function of circRNAs in hepatocellular carcinoma (HCC), the present invention used bioinformatics to analyze the circRNA expression profiles in 6 pairs of HCC tissues and adjacent tissues in the GEO database (dataset number: GSE164803). The results showed that circIST1 (hsa_circ_0005016) was the most significantly expressed and unreported circRNA. The expression of circIST1 in liver cancer patient tissues was further analyzed by qRT-PCR technology. The results showed that in 80 pairs of liver cancer and adjacent tissues, the expression of circIST1 was significantly higher than that of adjacent normal tissues. In addition, liver cancer patients with high expression of circIST1 had a poor clinical prognosis, including lower overall survival and disease-free survival rates. The results suggest that circIST1 is involved in the malignant progression of liver cancer and can be used as a potential diagnostic and therapeutic target.

[0010] Since circIST1 was discovered for the first time, the present invention identified its circular structure. Total RNA of liver cancer cell lines HCCLM3 and Hep3B cells was extracted, and reverse PCR amplification was performed using circIST1 functional region specific primers or IST1 common primers, and the amplified products were separated by agarose gel electrophoresis. The data showed that both characteristic primers and common primers could amplify circIST1, but linear IST1 could only be amplified using common primers. HCCLM3 and Hep3B cells were treated with RNase R, and the expression of IST1 or circIST1 was detected by RT-qPCR. The results showed that RNase R could significantly reduce the expression of IST1, but did not affect the expression of circIST1. In addition, the present invention treated HCCLM3 and Hep3B cells with actinomycin D for 6, 12 and 24 hours, and then detected the mRNA of IST1 or circIST1. The data showed that the half-life of circIST1 was longer than that of IST1. The qRT-PCR results showed that circIST1 was mainly located in the cytoplasm of HCCLM3 and Hep3B cells, indicating that circIST1 may have the function of miRNA sponge.

[0011] Based on the above technical solution, the first aspect of the present invention provides a circular RNA molecule circIST1, whose nucleotide sequence is shown in SEQ ID No.1:

[0012] GTTGCTGATCAGCTCTGTGCCAAGTATAGCAAGGAATATGGCAAGCTATGTAGGACCAACCAGATTGGAACTGTGACAGGCTAATGCACAAGCTGAGTGTGGAAGCCCCACCCAAAATCCTGGTGGAGAGATACCTGATTGAAATTGCAAAGAATTACAACGTACCCTATGAACCTGACTCTGTGGTCATGGCAGAAGCTCCTCCTGGGGTAGAGACAGATCTTATTGATGTTGGATTCACAGAT GATGTGAAGAAAGGAGGCCCTGGAAGAGGAGGGAGTGGTGGCTTCACAGCACCAGTTGGTGGACCTGATGGAACGGTGCCAATGCCCATGCCCATGCCCATGCCTATGCCATCTGCAAATACGCC TTTCTCATATCCACTGCCAAAGGGACCATCAGATTTCAATGGACTGCCAATGGGGACTTATCAGGCCTTTCCCAATATTCATCCACCTCAGATACCAGCAACTCCCCCATCGTATGAATCT(SEQ ID No.1).

[0013] Furthermore, the present invention also provides the back-splicing junction site of circIST1 ( Figure 1 ).

[0014] A second aspect of the present invention provides use of a reagent for detecting the expression level of circIST1 in preparing a liver cancer diagnosis kit.

[0015] Furthermore, the circIST1 is used as a liver cancer diagnostic marker in the preparation of a liver cancer diagnostic kit.

[0016] Furthermore, the kit comprises a reagent for detecting the expression level of circIST1 in a biological sample.

[0017] Furthermore, the biological sample is selected from: fresh tissue or cells obtained from a subject, formalin-fixed or paraffin-embedded tissue or cells, blood or body fluid.

[0018] The present invention found that the expression level of circIST1 in tumor tissue was significantly higher than that in adjacent normal tissue, indicating that circIST1 may be involved in the malignant progression of HCC and can be used as a biomarker for the diagnosis of HCC ( Figure 4 ).

[0019] A third aspect of the present invention provides use of a reagent for detecting the expression level of circIST1 in preparing a kit for evaluating the prognosis of liver cancer patients.

[0020] Furthermore, the circIST1 is used as a liver cancer prognosis assessment marker in the preparation of a kit for determining the prognosis of liver cancer patients.

[0021] Furthermore, in the application described above, patients with liver cancer who highly expressed circIST1 had a poor clinical prognosis, including a low overall survival rate and a low disease-free survival rate.

[0022] Furthermore, the reagent for detecting the expression level of circIST1 is selected from: a probe, a gene chip, or a PCR primer that has detection specificity for the expression level of circIST1.

[0023] Furthermore, the PCR primers with detection specificity for the expression level of circIST1 have nucleotide sequences as shown in SEQ ID No. 2 and SEQ ID No. 3, respectively:

[0024] Forward primer: GGGGACTTATCAGGCCTTTC (SEQ ID No. 2)

[0025] Reverse primer: GCTTGTGCATTAGCCTGTCA (SEQ ID No. 3).

[0026] Furthermore, the reagents for detecting the expression level of circIST1 include: a circIST1 extraction reagent, a reverse transcription reagent, a real-time quantitative PCR reagent, and a circIST1 real-time quantitative PCR primer, and the primer sequences are shown in SEQ ID NO.2 and SEQ ID NO.3.

[0027] In a fourth aspect of the present invention, a kit for diagnosing and evaluating the prognosis of liver cancer is provided, wherein the kit comprises a reagent for detecting the expression level of circIST1.

[0028] Furthermore, the reagent for detecting the expression level of circIST1 includes: PCR primers with detection specificity for the expression level of circIST1, and the nucleotide sequences thereof are shown in SEQ ID NO: 2 and SEQ ID NO: 3, respectively.

[0029] A fifth aspect of the present invention provides use of an agent for silencing or inhibiting circIST1 expression in the preparation of a drug for treating liver cancer.

[0030] Furthermore, the agent for silencing or inhibiting the expression of circIST1 is selected from:

[0031] A) Specific interference with circIST1 gene expression, processed small interfering RNA molecules, short hairpin RNA or antisense nucleotides;

[0032] B) Recombinant viral vector for silencing or inhibiting circIST1 expression.

[0033] Furthermore, the recombinant viral vector for silencing or inhibiting circIST1 expression is a circIST1 lentiviral silencing vector.

[0034] The present invention shows through in vivo and in vitro experiments that silencing the expression of circIST1 in liver cancer can promote the negative regulatory effect of miR-140-3p and miR-182 on HIF-1α, thereby inhibiting the expression of HIF-1α and preventing the malignant proliferation and metastasis of liver cancer cells.

[0035] In a sixth aspect of the present invention, a drug for treating liver cancer is provided, wherein the active ingredient is an agent that silences or inhibits the expression of circIST1.

[0036] Furthermore, the drug for treating liver cancer also includes a pharmaceutically acceptable carrier or excipient.

[0037] The present invention has the advantages that:

[0038] 1. This invention discovered a new liver cancer-related circRNA for the first time and named it circIST1. This invention confirmed that circIST1 is involved in the malignant progression of liver cancer and can be used as a potential diagnostic and therapeutic target. The expression level of circIST1 in patients can provide scientific, precise and personalized diagnosis and treatment plans for liver cancer patients.

[0039] 2. The present invention provides evidence that circIST1 is associated with the diagnosis and prognosis of liver cancer. Experimental results show that the expression of circIST1 is significantly higher than that of adjacent normal tissues. Liver cancer patients with high expression of circIST1 have a poor clinical prognosis, including a lower overall survival rate and disease-free survival rate, indicating that it can be used as a new biomarker for the diagnosis and prognosis evaluation of liver cancer patients and for the preparation of a liver cancer diagnosis and prognosis evaluation kit.

[0040] 3. The present invention provides the use of circIST1 as a therapeutic target for liver cancer. Silencing the expression of circIST1 in liver cancer can promote the negative regulatory effect of miR-140-3p and miR-182 on HIF-1α, thereby inhibiting the expression of HIF-1α and preventing the malignant proliferation and metastasis of liver cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 .Chromosome localization and sequence identification of CircIST1.

[0042] Figure 2 .CircIST1 was treated with RNA hydrolase to identify its circular structure.

[0043] Figure 3 . circIST1 was treated with actinomycin D to identify its circular structure.

[0044] Figure 4 .qRT-PCR was used to detect the expression of CircIST1 in liver cancer.

[0045] Figure 5 .CCK8 experiment detected the effect of silencing circIST1 on the proliferation of liver cancer cells.

[0046] Figure 6 .The clone formation experiment was used to detect the effect of silencing circIST1 on the proliferation of liver cancer cells.

[0047] Figure 7 .Transwell assay was used to detect the effect of silencing circIST1 on the migration and invasion of liver cancer cells.

[0048] Figure 8 .Based on the nude mouse subcutaneous tumor model, the effect of silencing circIST1 on the growth of liver cancer tumors was investigated. DETAILED DESCRIPTION

[0049] The specific implementation methods provided by the present invention are described in detail below in conjunction with examples.

[0050] The technology involved in the present invention is a conventional molecular cloning technology. The enzymes, primers, reagents and reaction conditions involved therein can be reasonably selected according to the experience of those skilled in the art unless otherwise specified. The reagents and consumables involved therein are ordinary products available on the market, and the detection methods and instruments involved therein are well known and mastered by those skilled in the art. Unless otherwise specified, each experimental method in the examples adopts existing experimental method steps and is strictly performed in accordance with the instructions of the kit manufacturer.

[0051] Embodiment 1:

[0052] In this example, a specific primer pair capable of amplifying circular RNA IST1 was designed, and circIST1 was amplified using the primer pair. The back-splice site of the circular RNA was confirmed by first-generation sequencing. Then, circIST1 was determined to be a circular RNA molecule with a closed circular structure through an RNase R digestion experiment. The stability of circIST1 was confirmed by an actinomycin D experiment.

[0053] The solution is as follows:

[0054] Total RNA was extracted from HCC cells using Trizol reagent, and the purity and concentration of total RNA in cells were detected using an ultra-micro nucleic acid analyzer. The reverse transcription reaction system was prepared on ice, and after the preparation, the prepared total RNA in cells was added for reverse transcription. The reverse transcription reaction system was:

[0055]

[0056] The reaction conditions are as follows:

[0057] The reaction was carried out at 37°C for 15 minutes, and then at 85°C for 5 seconds. After cooling to 4°C, the cDNA obtained by the reaction was diluted 5 times and then stored in a -20°C refrigerator.

[0058] Amplification was performed using the following primer designs:

[0059] Forward primer: GGGGACTTATCAGGCCTTTC (SEQ ID No. 2)

[0060] Reverse primer: GCTTGTGCATTAGCCTGTCA (SEQ ID No. 3)

[0061] After amplifying the cDNA obtained by reverse transcription using the above primers, the amplified product was sequenced. Figure 1 As shown, circIST1 originates from the 6th to 9th exons of gene IST1. The results of first-generation sequencing prove that circIST1 has reverse splicing connection and accurately displays the splicing site of the amplified product, indicating that the formation of circIST1 is not due to recombination mismatch of the genome.

[0062] 1. RNase R digestion experiment:

[0063] Total RNA was extracted from HCC cells using Trizol reagent, and 3 μg of total RNA was treated with RNase R (Epicentre, 10 U, 37°C, 30 min), followed by incubation at 70°C for 10 min to inactivate the RNase R enzyme, and then the relative RNA expression levels of circIST1 and mIST1 were compared by real-time PCR analysis. Figure 2 As shown, the expression of linear mIST1 was significantly reduced after RNase R digestion, while circIST1 was resistant to RNase R digestion, confirming that circIST1 has a circular structure.

[0064] 2. Actinomycin D experiment:

[0065] HCC cells were treated with actinomycin D (2 μg / ml) for 0, 4, 8, 12, and 24 h, and the expression levels of circIST1 and mIST1 were detected by real-time PCR and normalized by the values ​​of the 0-h group. Figure 3 As shown, the half-life of circIST1 was longer than that of mIST1, demonstrating the stability of circular RNA circIST1.

[0066] Embodiment 2:

[0067] In this example, the expression difference of circIST1 in liver cancer tissue and its adjacent normal tissue was detected by fluorescence quantitative PCR, and it was found that the expression of circIST1 in liver cancer tissue was significantly higher than that in the corresponding adjacent normal tissue, indicating that liver cancer can be diagnosed by detecting the expression level of circIST1.

[0068] The implementation plan is as follows:

[0069] Total RNA from tumor tissues was extracted using a total RNA isolation kit according to the manufacturer's instructions, and real-time PCR analysis was performed using ChamQTMSYBR@qPCR Master Mix. The relative expression of RNA was normalized to β-actin and expressed by 2 -ΔΔCt Legal amount.

[0070] The cDNA reverse transcription reaction in Example 1 was used to perform tissue RNA reverse transcription.

[0071] The primer pair used to amplify circular RNA adopts the preferred primer pair in Example 1:

[0072] Forward primer: GGGGACTTATCAGGCCTTTC (SEQ ID No. 2)

[0073] Reverse primer: GCTTGTGCATTAGCCTGTCA (SEQ ID No. 3)

[0074] The reaction conditions include:

[0075] Step 1: Pre-denaturation

[0076] 95°C, 5 minutes;

[0077] Step 2: PCR reaction (40 cycles)

[0078] 95°C, 20 seconds; 60°C, 20 seconds; 72°C, 20 seconds.

[0079] Step 3: Melting curve analysis

[0080] 65°C, 5 seconds; 95°C, 5 seconds.

[0081] Quantitative analysis was performed after PCR amplification. The formula for calculating the relative expression of the target gene was: 2-△△Ct=2-[(△Ct)Test-(△Ct)Control]. Among them, △Ct=Cttarget-Cthousekeeper, Cttarget is the Ct value of the target gene, Cthousekeeper is the Ct value of the housekeeper gene, △Ct represents the relative Ct value of the target gene of each sample relative to the housekeeper gene, △△Ct=(△Ct)Test-(△Ct)Control, indicating that the treatment group is normalized relative to the control group, 2-△△Ct represents the relative expression of the treatment group relative to the control group, and represents the relative expression multiple of the target gene.

[0082] The above qPCR experimental results are as follows Figure 4 As shown. Figure 4 It can be seen that the expression level of circIST1 in tumor tissues is significantly higher than that in adjacent normal tissues, indicating that circIST1 may be involved in the malignant progression of HCC and can be used as a biomarker for the diagnosis of HCC.

[0083] Embodiment 3:

[0084] In this example, in order to evaluate the biological function of circIST1 in the progression of HCC, the endogenous circIST1 expression levels of the cell lines HCCLM3 and Hep3B were examined, and the circIST1 lentiviral silencing vector and control vector were constructed, and stable infection was performed according to standard procedures. The lentiviral vector was synthesized by Hanbio Biotech (Shanghai) Co., Ltd.

[0085] CCK-8 proliferation and cloning experiments revealed that silencing circIST1 could significantly inhibit the proliferation of HCC cells. Transwell migration and invasion experiments confirmed that silencing circIST1 could significantly inhibit the migration and invasion of HCC cells. The above experiments showed that circIST1 plays a regulatory role in the malignant progression of HCC and can be used as a target for HCC treatment.

[0086] 1. The specific facts and plans of CCK8 and clone formation experiments are as follows:

[0087] Cell activity was detected by CCK8 assay. HCC cell suspension was prepared with a concentration of 3 × 10 4 / mL, 100 μL / well was inoculated in a 96-cell well plate, 10 μL CCK8 reagent was added at 0 hour, 24 hours, 48 ​​hours and 72 hours, respectively, and the cells were incubated at 37°C for 2 hours. The absorbance was detected at a wavelength of 450 nm using an enzyme reader.

[0088] The results are as follows Figure 5The results showed that silencing circIST1 could significantly inhibit the activity of HCC cells and significantly slow down the cell growth rate.

[0089] The cell proliferation ability was detected by clone formation experiment. HCC cell suspension was prepared, 500 cells were inoculated per well, and inoculated into 6-well cell culture plates. After 7 days, 1% crystal violet stain was used for staining to observe the number of cell clones.

[0090] Figure 6 The results showed that silencing circIST1 could significantly inhibit the number of HCC cell clones and significantly reduce the cell proliferation ability.

[0091] 2. Cell migration and invasion assay.

[0092] Transwell chambers (8.0 μm pore size, Corning Costar, Kennebunk, USA) were used with or without Matrigel coating (invasion assay). For cell migration assay, 2×10 cells suspended in 500 μL serum-free 1640 medium were cultured. 4 For the Matrigel invasion assay, 4 × 10 cells suspended in 500 μL serum-free 1640 medium were seeded into the upper chamber of a 24-well plate. 4 Cells were seeded into the upper chamber of a 24-well plate, and 1640 culture medium containing 10% FBS was added to the lower chamber. After 24 or 48 hours, the cells that migrated or invaded the lower surface of the lower chamber were fixed and stained with paraformaldehyde and then observed under a microscope.

[0093] like Figure 7 The results showed that silencing circIST1 could significantly inhibit the migration and invasion ability of HCC cells.

[0094] Embodiment 4:

[0095] In this example, in order to study the effect of circIST1 on HCC tumor growth, a HCC nude mouse subcutaneous tumor model was constructed, and circIST1 stably silenced HCC cells established by lentiviral transfection were subcutaneously implanted to observe the effect of silencing circIST1 on tumor growth.

[0096] BALB / c nude mice aged 5 to 6 weeks were used. For the nude mouse subcutaneous tumor model, 5×10 6 Stably transfected HCC cells were subcutaneously injected into the right posterior back of nude mice. After inoculation, the length and width of the tumor were recorded every week, and the tumor volume (V = 1 / 2 × a × b 2 , a is the long diameter, b is the short diameter). Starting from the second week, the tumor volume was measured and recorded every other week. After five weeks, the nude mice were killed and the weight of the subcutaneous tumor was measured.

[0097] The experimental results are as follows Figure 8 As shown in the figure, after silencing circIST1 expression, tumor growth was significantly inhibited.

[0098] The preferred embodiments of the present invention have been specifically described above, but the present invention is not limited to the embodiments. Those skilled in the art may make various equivalent modifications or substitutions without violating the spirit of the present invention. These equivalent modifications or substitutions are all included in the scope defined by the claims of this application.

Claims

1. A circular RNA molecule circIST1, whose nucleotide sequence is shown in SEQ ID No.

1.

2. Application of reagents for detecting the expression level of circIST1 in the preparation of liver cancer diagnostic kits.

3. Application of reagents for detecting the expression level of circIST1 in the preparation of a prognosis assessment kit for liver cancer patients.

4. The use according to claim 2 or 3, It is characterized in that The reagent for detecting the expression level of circIST1 is selected from: a probe, a gene chip, or a PCR primer that has detection specificity for the expression level of circIST1.

5. The use according to claim 4, It is characterized in that The PCR primers with detection specificity for the expression level of circIST1 have nucleotide sequences as shown in SEQ ID No. 2 and SEQ ID No. 3, respectively.

6. A kit for liver cancer diagnosis and prognosis assessment, It is characterized in that The kit contains a reagent for detecting the expression level of circIST1.

7. Use of reagents for silencing or inhibiting circIST1 expression in the preparation of drugs for the treatment of liver cancer.

8. The use according to claim 7, It is characterized in that The reagent for silencing or inhibiting circIST1 expression is selected from: A) Specific interference with circIST1 gene expression, processed small interfering RNA molecules, short hairpin RNA or antisense nucleotides; B) Recombinant viral vector for silencing or inhibiting circIST1 expression.

9. The use according to claim 7, It is characterized in that The recombinant viral vector for silencing or inhibiting the expression of circIST1 is a circIST1 lentiviral silencing vector.

10. A drug for treating liver cancer, wherein the active ingredient is an agent that silences or inhibits the expression of circIST1.